The AbbVie Update: Q1 Spotlight On Life After Humira (NYSE:ABBV)

hamzaturkkol

2023 shall be an enormous 12 months for AbbVie. The corporate’s transition from a Humira-dependent enterprise to 1 with a number of inexperienced shoots is right here. Is administration’s years of preparation working?

AbbVie’s Q1 outcomes

AbbVie reported Q1 outcomes on Aprilgrappling with the lack of Humira revenues

AbbVie stock

Knowledge supply: AbbVie. Chart by creator.

AbbVie Skyrizi and Rinvoq sales

Knowledge supply: AbbVie. Chart by creator.

Back To Top